Clinical trial · Interventional
Identifying Molecular Alterations to Guide Individualized Treatment in Advanced Solid Tumors
Identifying Molecular Alterations to Guide Individualized Treatment in Advanced Solid Tumors-PERMED01-IPC 2014-003
NCT02342158CI-TRIAL-00108864PERMED01completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
PERMED01 is a prospective monocenter clinical trial which aims to evaluate the number patients with locally advanced or metastatic cancer for whom identification of molecular alterations in tumor samples can lead to the delivery of a targeted therapy. PERMED01 will enroll 460 patients in 3 years.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasm Metastasis | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| biopsy or surgical sampling | Procedure | — | UNRESOLVED |
| blood sampling | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Locally advanced /metastatic cancer
- interventionNames
- Procedure: biopsy or surgical sampling
- Other: blood sampling
Primary outcomes (1)
- measure
- proportion of screened patients in whom a molecular abnormality for which a targeted therapy exists
- timeFrame
- 4-6 weeks after biopsy
Secondary outcomes (5)
- measure
- Molecular Characterization of locally advanced and metastatic malignancies using next generation sequencing
- timeFrame
- 3.5 years
- measure
- Full exome and transcriptome sequencingof locally advanced and metastatic tumours
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age\>18 years * Histological diagnosis of cancer * Locally advanced or metastatic, biopsiable disease * ECOG Performans Status ≤2 * Affiliation to social security * Signed informed consent. Exclusion Criteria: * Emergency, Individually deprived of liberty or placed under the authority of a tutor * Patients with symptomatic or progressive brain metastasis * Patients who have only bone and/or brain metastases * Pregnant or breastfeeding women
References
Publications (2)
- RESULTBertucci F, Goncalves A, Guille A, Adelaide J, Garnier S, Carbuccia N, Billon E, Finetti P, Sfumato P, Monneur A, Pecheux C, Khran M, Brunelle S, Mescam L, Thomassin-Piana J, Poizat F, Charafe-Jauffret E, Turrini O, Lambaudie E, Provansal M, Extra JM, Madroszyk A, Gilabert M, Sabatier R, Vicier C, Mamessier E, Chabannon C, Pakradouni J, Viens P, Andre F, Gravis G, Popovici C, Birnbaum D, Chaffanet M. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. Genome Med. 2021 May 18;13(1):87. doi: 10.1186/s13073-021-00897-9. PMID 34006291
- RESULTSabatier R, Garnier S, Guille A, Carbuccia N, Pakradouni J, Adelaide J, Provansal M, Cappiello M, Rousseau F, Chaffanet M, Birnbaum D, Mamessier E, Goncalves A, Bertucci F. Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial. Front Oncol. 2022 Jul 29;12:946257. doi: 10.3389/fonc.2022.946257. eCollection 2022. PMID 35965534